AKT1 and hepatocellular carcinoma: Our current study shows that the other upstream pathways other than the tyrosine kinase receptor (RTK) signal activate AKT signaling and the AKT phosphorylation levels increase in sorafenib-resistant HCC cells and tissues, which is consistent with previous finding 8.